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Introduction 
 
Zheng Xiaoyu, the former director of National Food and Drug Administration of the 
PRC was executed in Beijing on July 10, 2007.  From June 1997 to December 2006, 
Zheng  Xiaoyu  had  accepted  bribery  from  eight  pharmaceutical  companies  while 
examining and approving their drugs and medical devices.  In addition, from 2001 to 
2003, Zheng Xiaoyu had illegally lowered the standard of examining and approving 
drugs, which resulted many unqualified drugs being approved.  It was later discovered 
that six of the approved drugs are counterfeit drugs.
1  The case of Zheng Xiaoyu 
raised  great  public  attention  on  the  issue  of  drug  safety.    Both  the  voices  from 
academia and government called for reform and improvement of the drug regulation 
system, especially the new drug regulation system, viz. new drug examination and 
approval.   
 
The  new  drug  examination  and  approval  system  was  established  in  the 
Pharmaceutical Administration Law which was issued by the Standing Committee of 
National People’s Congress and elaborated in the Measures for the Administration of 
Drug Registration (hereinafter referred as “the Measures”) which were promulgated 
by the State Food and Drug Administration (hereinafter referred as “SFDA”) on May 
1, 2005.  The Measures have the same function in China as regulations do in the 
                                                        
1 Xin hua wang [Xinhua Net], Jing zui gao Renmin Fayuan he zhun Zheng Xiaoyu 10 ri Shangwu bei zhi xing 
Sixing [Approved by the Supreme Court, Zheng Xiaoyu was Executed in the Morning of the 10
th] (July 10, 2007), 
http://news.xinhuanet.com/legal/2007-07/10/content_6353841.htm.   4 
United States.  On October 1, 2007, the Measures were amended (hereinafter referred 
as  the  “2007  Amendment”),  which  brought  significant  changes  to  the  new  drug 
examination and approval system.   
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Abstract 
 
This paper analyzes the new drug examination and approval systems before and after 
the  Measures  was  amended  in  2007  and  evaluates  the  effectiveness  of  the  2007 
Amendment. 
 
In Part One, this paper introduces the new drug examination and approval system 
before the Measures were amended in 2007 and analyzes its disadvantages.  Part Two 
of the paper describes the changes brought by the 2007 Amendment to the Measures 
and evaluates their effectiveness with regard to drug safety.  Part Three discusses the 
impacts of the Agreement between the Department of Health and Human Services of 
the United States of America and the SFDA of the People’s Republic of China on the 
Safety of Drugs and Medical Devices on Chinese new drug regulation system.  In the 
end,  the  author  concludes  that  although  the  tendency  of  stricter  supervision  of 
government authority is obviously beneficial for the guarantee of drug safety, the 
effective implementation of the legal schemes is still a big issue in China.   
 
Part  One:  The  New  Drug  Regulation 
System before the 2007 Amendment 
   6 
The main statute establishing the new drug regulation system is the Pharmaceutical 
Administration  Law.    It  was  adopted  by  the  Seventh  Session  of  the  Standing 
Committee  of  the  Fifth  National  People’s  Congress  on  September  20,  1984, 
implemented on July 1, 1985, and then amended at the Twentieth Meeting of the 
Standing Committee of the Ninth National People’s Congress on February 28, 2000 
and entered into force as of December 1, 2001.  Article 31 of the Pharmaceutical 
Administration Law of the PRC requires that the production of new drugs shall be 
approved by the drug supervision and administration agency in State Council,
2 which 
implements  the  drug  approval  system  in  China.    “The  drug  supervision  and 
administration  agency  in  State  Council  authorizes  the  drug,  medical  and  other 
technical experts to review Uhe new drugs.”
3   
 
The  provisions  on  the  new  drug  registration  system  in  the  Pharmaceutical 
Administration Law are very vague and abstract.  Therefore, the SFDA promulgated 
the  Measures  which became  effective on  May  1,  2005.   The  Measures  provide  a 
concrete scheme of new drug examination and approval.  According to the Measures, 
the application for new drugs includes “the applications for the registration of drugs 
that have not been marketed within China,”
4 In addition, “if the type of preparation or 
the route of administration of any drugs that have been marketed is changed, or if the 
range of indications thereof is newly expanded, the said drugs shall be treated as new 
                                                        
2 Pharmaceutical Administration Law (promulgated by the Standing Comm. National People’s Cong., Feb. 28, 
2001, effective Dec. 1, 2001), art. 31, translated in CHINALAWINFO (last visited April 5, 2008) (P.R.C.). 
3 Id. Art. 33. 
4 Measures for the Administration of Drug Registration (promulgated by the State Food and Drug Administration, 
Feb. 28, 2005, effective May 1, 2005), art. 8, sec. 1, translated in CHINALAWINFO (last visited April 5, 2008) 
(P.R.C.).   7 
drugs.”
5  Therefore, the scope of a new drug application is relatively broad under the 
Measures.  Because the applications are filed in writing, the Measures require that 
“the  materials  submitted  for  the  registration  of  new  drugs  shall  be  complete  and 
normative, and the data must be true and reliable.”
6  The Measures also include a 
series  of  requirements  on  the  examination  and  approval  of  clinical  trials  and 
manufacture of new drugs. 
 
I. Examination and Approval of Clinical Trials of New 
Drugs 
 
The  examination  and  approval  of  clinical  trials  of  new  drugs  is  an  important 
component of new drug regulation.  While applying for the registration of a new drug, 
an applicant is required to conduct clinical trials, which are classified into four phases: 
I,  II,  III  and  IV.    Generally  speaking,  phases  I,  II,  and  III  clinical  trials  shall  be 
conducted before a new drug is approved for marketing.
7   
 
The phase I clinical trial: the preliminary trials on clinical pharmacology 
and human body safety evaluation, which aim to observe the degree of 
tolerance of human body against the new drug and the drug dynamics, and 
provide the basis for working out the dosage administration scheme.   
                                                        
5 Id. 
6 Id. Art. 47. 
7 Id. Art. 24, Sec. 2. (Under certain circumstances, the applicant may, upon approval, only conduct phases II and III 
clinical trials or only phase III clinical trials.)   8 
 
The phase II clinical trial: the preliminary evaluation of the treating effects, 
which aim to preliminarily evaluate the treating effect and safety of the 
drug on the target patients with the applicable disease, and also to provide 
the  basis  for  the  determination  of  the  study  design  and  dosage 
administration scheme for the clinical trials in phase III.   
 
The phase III clinical trial: the confirmation phase of the treating effect, 
which aims to further verify the treating effect and safety of the drug on the 
target  patient  with  the  applicable  disease,  to  evaluate  the  relationship 
between benefit and risk, and to eventually provide an adequate basis for 
the examination of the drug registration application.   
 
The phase IV clinical trial: the phase of application study conducted by the 
applicant independently after the new drug comes into the market, which 
aims to examine the curative effect of the drug and the adverse reactions 
when it is widely used, to evaluate the relationship between benefit and 
risk when the drug is used in ordinary or special groups and to improve the 
dosage, administration, etc.
8   
 
Because of the importance and impact of clinical trials, the Measures provides the 
                                                        
8 Id. Art. 24.   9 
application and review procedures before conducting clinical trials.   
 
First,  “an  applicant  shall  fill  in  the  Application  Form  for  Drug  Registration,  and 
faithfully submit the relevant materials and drug samples to the local (food) drug 
administration of the province, autonomous region or municipality directly under the 
Central  Government a fter  finishing  the  pre-clinical  trial  of  new  drugs.”
9   The 
examination and approval of clinical trials of new drugs is composed of formal and 
substantial reviews.  The (food) drug administrations of the province, autonomous 
region, or municipality directly under the Central Government which are in charge of 
the examination of the application materials shall conduct a formal review of the 
application materials.  “If the application materials meet the relevant requirements, it 
shall accept them and give the applicant an application acceptance notice.  If they do 
not meet the relevant requirements, it shall give the applicant a rejection notice of 
application with corresponding explanation.”
10   
 
Besides the review of application materials, the (food) drug administrations of the 
province, autonomous region or municipality directly under the Central Government 
also conduct on-spot inspections before approving to carry out clinical trials.  They 
shall organize an on-spot inspection “within 5 days after they accept the application, 
take 1-3 samples for inspection use and send a notice about the registration inspection 
                                                        
9 Id. Art. 52. 
10 Id. Art. 53, Sec. 1.    10 
to the designated institute for drug control.”
11  In the end, they shall also “submit the 
examination opinions, inspection report and application materials to the State Food 
and Drug Administration and notify the applicant within the prescribed time limit.”
12 
The institute for drug control which receives the notice about registration inspection 
from the drug administrations will then “check and test the samples, verify the drug 
standards  of  the  application,  and  submit  the  inspection  report  and  verification 
opinions to the SFDA, the (food) drug administrations of the province, autonomous 
region,  or  municipality  directly  under  the  Central  Government  which  sent  the 
inspection notice to it, and the applicant.”
13   
 
At this time, all the relevant materials and information are held by the SFDA, which is 
in  charge  of  conducting  the  substantial  review  of  the  application.  The  SFDA 
organizes  technicians  of  pharmacology,  iatrology  and  other  subjects  to  conduct 
technical  evaluation  of  the  new  drug.    If  it  believes  that  the  applicant  meets  the 
pertinent provisions, it shall issue it an Approval of Drug Clinical Trial. Otherwise, it 
shall give it a Notice of Examination Opinions with corresponding explanation.
14   
 
One critical issue in the review process for clinical trials is the controllability of the 
quality of the new drug.  The following requirements apply to the clinical trials.  If the 
institute  for  drug  control  considers  that  the  drug  standards  applied  are  unable  to 
                                                        
11 Id. Art. 53, Sec. 2. 
12 Id. 
13 Id. Art. 54. 
14 See Id. Art. 55.   11 
control  the  quality,  the  applicant  may  withdraw  the  new  drug  application.  If  the 
applicant fails to withdraw its application and later the SFDA considers that the drug 
standards  are  really  unable  to  control  the  quality,  the  application  will  not  be 
approved.
15  In order to get approval, the samples taken from the on-spot inspection 
shall also meet relevant drug standards.  “If, upon inspection, any sample does not 
conform  to  the  drug  standards  for  which  the  applicant  applies,  the  SFDA  shall 
disapprove the new drug application.”
16   
 
The examination of an application for new drug registration should be generally based 
on  materials  submitted  in  the  beginning.    The  only  exceptions  provided  in  the 
Measures are for “the creative ingredients of the drug or new discoveries involving 
the  drug  safety.”
17   Otherwise,  the  applicant  shall  not  supplement  the  original 
application with any new technical materials.  “If the applicant insists that it must 
supplement  some  technical  materials,  it  shall  withdraw  its  drug  registration 
application and file a new one after it has prepared a complete set of materials.”
18   
 
II.  Examination  and  Approval  of  the  Manufacture  of 
New Drugs 
 
After finishing the clinical trials of drugs, it is time to file an application for new drug 
                                                        
15 See Id. Art. 56. 
16 Id. Art. 57. 
17 Id. Art. 58. 
18 Id.    12 
registration.    This  is  also  the  phase  when  a  lot  of  corruption  and  fraud  happens.  
According to the Measures,  
 
an  applicant  shall  fill  out  an  Application  Form  for  Drug  Registration, 
submit the clinical trial materials and other modified and supplemented 
materials to the (food) drug administration of the province, autonomous 
region or municipality directly under the Central Government where it is 
located, explain the basis and reasons in details, and send the raw materials 
of  the  standard  products  to  the  National  Institute  for  the  Control  of 
Pharmaceutical and Biological Products at the same time.
19   
 
The  examinations  conducted  by  the  (food)  drug  administration  of  the  province, 
autonomous region, or municipality directly under the Central Government are also 
composed of formal and substantial examinations.  First of all, it shall conduct a 
formal examination over the application materials.  If it considers that the application 
materials  meet  the  relevant  requirements,  it  shall  accept  them  and  issue  to  the 
applicant a notification of acceptance of the drug registration application.  Otherwise, 
it  shall  reject  them  and  issue  to  the  applicant  a  notice  of  rejection  of  the  drug 
registration application with corresponding explanation.
20  Then, being similar to the 
requirements  in  examination  and  approval  of  clinical  trials,  the  (food)  drug 
administration of the province, autonomous region or municipality directly under the 
                                                        
19 Id. Art. 60. 
20 See Id. Art. 61.   13 
Central Government shall also organize an on-spot inspection “within 5 days after it 
accepts an application, select samples from the products of 3 successive production 
batch numbers, send a registration inspection notice to the designated institute for 
drug  control,  and  submit  the  examination  opinions,  investigation  report  and 
application  materials  to  the  SFDA  and  notify  the  applicant.”
21  
 
In the end, the SFDA will conduct the substantial examination and make the final 
decision based on whether the application materials meet the relevant requirements.  
If it considers that the application materials meet the relevant requirements, it shall 
issue the applicant an Approval Document on Drug Registration and a New Drug 
Certificate.  If the applicant holds a License for Drug Manufacturing and have the 
conditions for manufacturing the drug, the SFDA may simultaneously issue to the 
applicant  the  registered  number  of  drug  approval.    If  SFDA  considers  that  the 
application  materials  do  not  meet  the  relevant  requirements,  it  shall  issue  to  the 
applicant a Notice about the Examination Opinions with corresponding explanation.
22  
 
Based  on  the  description  above,  it  is  of  no  doubt  that  the  State  Food  and  Drug 
Administration is extremely powerful in the process of new drug examination and 
approval.  It possesses the sole authority to make substantial decisions on new drug 
applications.  The broad and apparently unlimited power unavoidably leads to the 
abuse of power and severe corruption.   
                                                        
21 Id. Art. 62. 
22 See Id. Art. 65.   14 
III.  Administration  of  the  Monitoring  Periods  of  New 
Drugs 
 
The  Measures  provide  another  important  mechanism  for  the  protection  of  public 
health: the monitoring period of new drugs.  “In order to protect public health, the 
SFDA may set forth monitoring periods for new drugs approved to be manufactured, 
to continually monitor the safety of those new drugs.  The SFDA will not approve 
other  enterprises  to  manufacture  or  import  new  drugs  within  the  monitoring 
periods.”
23 
 
The monitoring period of a new drug shows the government’s concern and caution on 
the impact of the new drugs on public health and safety.  According to the Measures, 
it is determined “on the basis of the existing safety research materials and the research 
status domestically and abroad.  In addition, it shall not exceed 5 years from the date 
of approval of manufacturing the drug.”
24  For a new drug, within the monitoring 
period the drug manufacturing enterprise carries a heavy burden on the inspection of 
drug manufacture.  It shall “regularly inspect the manufacturing techniques, quality, 
stability, curative effect and adverse reactions, etc., and make a report each year to the 
(food)  drug  administration  of  the  province,  autonomous  region  or  municipality 
directly under the Central Government where it is located.”
25  The Measures also have 
                                                        
23 Id. Art. 68. 
24 Id. Art. 69. 
25 Id. Art. 70.   15 
requirements on immediate reporting to the relevant government agency when “any of 
the entities relating to the manufacturing, operation, use, or inspection or supervision 
of  drugs  finds  that  the  new  drug  has  any  serious  quality  problem,  or  causes  any 
serious or unanticipated adverse reactions.”
26   
 
Another important impact of the monitoring period is on the identical registration 
application filed by other applicants.  The Measures provide that “from the day when 
a new drug enters the monitoring period, no identical registration application filed by 
any  other  applicant  may  be  accepted.”
27   This  provision  is  also  beneficial  for  the 
public health in case potential adverse reactions are caused by the new drugs within 
the monitoring period. 
 
IV. Legal Liabilities 
 
The  Pharmaceutical  Administration  Law  includes  a  series  of  provisions  on  legal 
liabilities of the government officials.  If government officials abuse their authority to 
such  an  extent  that  a  crime  is  committed,  they  shall  be  investigated  for  criminal 
liabilities.    If  their  acts  have  not  constituted  a  crime,  they  shall  be  subject  to 
administrative sanctions.
28  Article 203 of the Measures provides that  
 
                                                        
26 Id.  
27 Id. Art. 75. 
28 See  Pharmaceutical  Administration  Law,  art.  99,  translated  in  CHINALAWINFO  (last  visited  April  5,  2008) 
(P.R.C.).   16 
“if  the  SFDA,  or  the  (food)  drug  administrations  of  a  province, 
autonomous region or municipality directly under the Central Government, 
or any of its staff member extorted or accepted any property of others or 
seek other benefits, he should be punished according to the Administrative 
License Law, which provides that for any of the functionaries who asks for 
or  accepts  the  property  of  others’  or  seeks  for  other  interests  when 
implementing  an  administrative  license  and  exercising  supervision  and 
inspection,  if  he  constitutes  a  crime,  he  shall  be  subject  to  criminal 
responsibilities; if the violation does not constitute a crime, he shall be 
given an administrative sanction in accordance with the law.”
29 
 
Although there are clear provisions on legal liability in the laws and regulations, they 
are  ignored  when  the  government  officials  are  endowed  broad  authority  without 
corresponding supervision mechanisms.  It is always the case that unlimited authority 
is  the  soil  for  the  growth  of  corruption.    According  to  the  Pharmaceutical 
Administration  Law,  the  examination  and  approval  authority  of  new  drugs  is 
substantially delegated to the national drug administration, viz. State Food and Drug 
Administration and provincial drug administrations.  This system is beneficial when 
there is highly efficient supervision, but it opens the door to bribery and corruption 
when the significant authority is controlled by high level government officials.  As we 
can  see  in  the  Zheng  Xiaoyu  Case,  because  there  are  not  sufficient  supervision 
                                                        
29 Id. Art. 73.   17 
mechanisms on the authority of government officials, the new drug examination and 
approval system is subject to the potential for serious corruption.   
 
Part Two: Reforms in the 2007 Amendment 
 
After  the  Zheng  Xiaoyu  Case,  the  Chinese  central  government  became  highly 
concerned with the issue of new drug regulation.  Because of its significant impact on 
public health and safety, this topic also attracted broad public attention.  In order to 
relieve public worry about drug safety, the National Drug Administration declared on 
January 15, 2007 that all the drugs in the market must be approved again.  Any drug 
which can not pass the examination has to be withdrawn from the market.
30   
 
Systematic reform was also on its way.  The Measures were amended on October 1, 
2007.  The 2007 Amendment covers many adjustments to the new drug examination 
and approval system.  In the context of structural reform, it added the chapter of 
“Basic  Requirements  for  Drug  Registration”,  and  deleted  “Application  of  Drug 
Registration”  and  “Pre-Clinical  Research  of  Drugs”  etc.    Although  the  2007 
Amendment does include other issues besides the reform of new drug regulation, this 
paper will only elaborate the amendments to the new drug examination and approval 
system.   
                                                        
30 Renmin Wang [Renmin Net], Guo jia yao jian ju yuan fu ju zhang Zheng Xiaoyu an fa jia su shen pi zhi du gaige 
[Zheng  Xiaoyu  Case  Promoted  the  Reform  of  the  Examination  and  Aproval  System]  (January  29,  2007), 
http://politics.people.com.cn/GB/1026/5336605.html.   18 
 
I. Narrower Scope of the New Drug Application 
 
The  2007  Amendment  narrowed  the  scope  of  the  new  drug  application  to  “the 
applications for the registration of drugs that have not been marketed within China.”
31  
The old definition also included the drugs, “the type of preparation or the route of 
administration of which is changed, or the range of indications is newly expanded.”
32  
Under the old definition, a large number of new drug applications were filed to the 
National Food and Drug Administration every year.  It is an overwhelming burden on 
the agency, considering its limited personnel and resources.  What is more, some 
pharmaceutical companies took advantage of this provision and obtained a number of 
new drug approvals for the same drug.  In this way, they raised the price of the drug 
and  got  illegal  benefit  by  cheating  on  uninformed  consumers.    Therefore,  the 
amendment to the definition of “new drug application” is beneficial both to the drug 
supervisory agency and the public. 
 
II.  Stricter  New  Drug  Examination  and  Approval 
Procedures 
 
                                                        
31 Measures for the Administration of Drug Registration, art. 12, translated in CHINALAWINFO (last visited April 5, 
2008) (P.R.C.). 
32 Id. Art. 8, Sec. 1.   19 
The  requirements  of  new  drug  examination  and  approval  procedures  are  stricter.  
Chapter Four of the Measures specifically provides for the application and approval of 
new drugs.   
 
The  amendment  introduces  more  mechanisms  to  ensure  the  authenticity  of  the 
application  materials.    According  to  the  Amendment,  “the  applicant  shall  provide 
reliable  research  data  to  prove  the  safety,  effectiveness  and  controllability  of  the 
quality of the drug.  The applicant should be responsible for the authenticity of all the 
materials.”
33  What happened in the past was that a lot of fake application materials 
were filed to the drug administration and were approved.  The Amendment put more 
responsibility on the applicants in this aspect.  However, without efficient supervision, 
the  applicants  will  not  have  any  incentive  to  follow  the  statutory  requirements.  
Therefore, in contrast to the former process which largely relied on reviewing written 
materials,  the  Amendment  stresses  the  importance  of  on-spot  inspection.    In  the 
process of new drug examination, the drug supervision and administration agency 
should conduct on-spot inspections of non-clinical research and clinical research, and 
an  on-spot  inspection  of  production  before  approval  for  marketing  in  order  to 
guarantee the authenticity, veracity and complicity of the application materials.
34  This 
mechanism is intended to discover possible fraud in the application materials and 
supervise compliance of the pharmaceutical companies. 
 
                                                        
33 Id. Art. 13. 
34 Id. Art. 16.   20 
III. More Supervision on Government Authority 
 
The most significant amendment is the restriction and supervision on examination and 
approval authority.  Unlimited authority is the unavoidable source of corruption and 
malpractice.  In order to prevent the abuse of authority by government officials in the 
process  of  the  examination  and  approval  of  new  drugs,  three  mechanisms  are 
provided  in  the  Amendment,  including  the  Chief  Umpire  and  Collective 
Responsibility System, Public Notification of Related Personnel and Publicity of all 
the Procedures of Examination and Approval.
35  The provision on the Chief Umpire 
and Collective Responsibility System ended the era when a single chief official could 
make all the decisions.  The introduction of collective responsibility is intended to 
bring  more  supervision  to  the  examination  and  approval  authority  held  by  the 
administrative agencies.  Public Notification of Related Personnel and the Publicity of 
all  the  Procedures  of  Examination  and  Approval  will  make  the  government 
procedures more transparent and bring in more public participation and supervision.  
The government opened information to the public and promoted public supervision of 
the authority of the government officials.  The three mechanisms definitely help to 
avoid and supervise the abuse of government authority. 
 
One of the major reasons why corruption in the new drug examination and approval 
system became such a huge problem is because of the lack of transparency in this 
                                                        
35 Id. Art. 6.   21 
process.  Although there is no clear provision in the Amendment about the public 
availability of information, new regulation titled the Provisions on the Disclosure of 
Government  Information  was  adopted  at  the  165th  standing  meeting  of  the  State 
Council on January 17th, 2007, and should come into force as of May 1st, 2008.  The 
term “government information” as mentioned in this regulation refers to “information 
produced or acquired and recorded or kept in certain forms by administrative agencies 
in the process of performing their responsibilities.”
36 
 
There are two ways for government information to be disclosed according to this 
regulation.  One way is called “Voluntary Disclosure.”  One category of information 
which  the  government  shall  voluntarily  disclose  is  about  “issues  subject  to 
administrative  approval  including  the  corresponding  basis,  requirements,  quantity, 
procedures, time limit and list of all the materials that shall be submitted for purposes 
of administrative approval.”
37  It is obvious that this category covers the new drug 
approval  information  held  by  the  government.    Therefore,  the  new  drug  approval 
information  is  required  to  be  disclosed  by  the  government  agencies  “within  20 
workdays of the day when such government information is formed or changed, unless 
there is any different requirement stipulated by other laws or regulations on the time 
limit for government information disclosure.”
38 
 
                                                        
36 Provisions on the Disclosure of Government Information (promulgated by the State Council, Jan. 17, 2007, 
effective May 1, 2008), art. 2, translated in CHINALAWINFO (last visited April 5, 2008) (P.R.C.). 
37 Id. Art. 10. 
38 Id. Art. 18.   22 
The  other  way  is  called  “requested  disclosure.”    In  addition  to  the  government 
information voluntarily disclosed by government agencies, citizens and organizations 
may apply for disclosure of other government information.  They may “in light of 
their special needs for manufacture, living or scientific research, etc., apply to the 
national departments under the State Council, the local governments at various levels 
and the departments of the local governments at or above the county level for access 
to  government  information.”
39   Although  this  provision  is  very  vague,  it  provides 
another venue to obtain relevant government information.  Even if the government 
agencies decide that the government information shall not be disclosed, the applicant 
shall be given reasons for the denial.  If the request for information disclosure was 
filed with the wrong agency, the agency shall notify the applicant of this fact and 
provide  the  name  and  contact  information  of  the  government  agency  which  the 
applicant  shall  request  for  information  if  possible.    Even  when  the  requested 
information does not exist, the applicant is also entitled to be notified of this fact.
40   
 
One possible barrier to get information disclosed lies in the protection of commercial 
secrets.  “No government agency may disclose any government information involving 
state secrets, commercial secrets or individual privacy.  However, in cases where the 
rights holder consents or when the government agency believes that the failure to 
disclose such information would impair public interests, such government information 
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may be disclosed.”
41  Commercial secrets may be involved in the materials for new 
drug  examination  and  approval.    However,  considering  the  intimate  relationship 
between drugs and public health and safety, it would be a very strong argument that 
failure to disclose such information would impair the public interest.  
 
If  the  government  refuses  to  disclose  the  information,  there  are  legal  remedies 
provided in the regulation.  There are supervisory agencies which are responsible for 
the investigation of malpractice in government agencies.  “Where any citizen, legal 
person or any other organization believes that a government agency fails to fulfill its 
obligation to disclose information according to the law, he/it may inform the superior 
government  agency,  supervisory  organ  or  the  competent  department  dealing  with 
government  information  disclosure.”
42   The  citizen,  legal  person,  or  organization 
which informs the supervisory agency does not need to prove any connection with the 
disclosure of information.  If they believe that their legal interest has been impaired 
by an administrative act, they can file an administrative lawsuit for judicial review of 
the agency action.
43  If the government agency fails to respond to the application for 
information disclosure, the applicant can file an administrative lawsuit in Chinese 
court.  It is good to see that the publicity requirement in the amended regulation does 
invite the possibility of public participation and supervision.   
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IV.  Evaluation  of  the  Effectiveness  of  the  2007 
Amendment 
 
Despite all the wonderful improvements in the amended regulation, there are still 
questions  left  about  the  effectiveness  of  the  new  mechanisms.    A  declarational 
provision in the law or regulation is not enough to make an effective legal mechanism.  
In order to guarantee that government officials will faithfully follow the requirements 
in  the  laws  and  regulations,  it  is  very  important  to  include  a  strong  legal 
accountability system for government officials.   
 
Under the current system, the supervisory agencies within the administrative branch 
take main responsibility for supervising government officials.  According to prior 
experience,  because  the  supervisory  agencies  are  not  independent  from  the 
administrative  branch,  their  supervision  has  been  quite  limited.    The  supervisory 
agencies need an independent status to fully exercise their authority. Otherwise their 
supervision can be seriously affected by the administrative agencies.  An efficient 
supervision system can disclose illegal behavior of government officials at an early 
stage, which could reduce the damage caused to the public and save the great expense 
of public advocacy or litigation.  Therefore, an independent and efficient supervisory 
branch would be a powerful mechanism against corruption. 
 
On  the  other  side,  public  supervision  is  also  a  powerful  tool.    The  disclosure  of   25 
government information serves as the first step to the process of public participation.  
Because the Provisions of on the Disclosure of Government Information is a newly 
issued regulation, there is not enough experience to evaluate its effectiveness under 
the current system.  Still it shows the determination and intention of the Chinese 
government to encourage public participation and supervision.  With the involvement 
of  the  public,  government  officials  will  definitely  become  more  careful  while 
performing their responsibilities.  Another major issue for public participation is to 
build  up  the  participation  capacity  of  the  public.    If  the  public  is  not  capable  of 
substantially supervising the government, the relevant legal schemes provided in the 
laws and regulations would become useless.  One common way to build up public 
capacity  and  promote  public  participation  is  through  the  non-government 
organizations.  In contrast to the robust non-government organizations in the US, the 
domestic non-government organizations in China have less access to intellectual and 
financial resources, which make organized public participation very difficult.  Even 
though the public can get access to government information, how to make good use of 
it is still a huge challenge for them.  Therefore, legal reform and the rule of law in 
China  still  have  a  long  way  to  go  both  in  the  legal  system  and  public  capacity 
building.   
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Part  Three:  China-U.S.  Cooperation  on 
Drug Regulation 
 
In  addition  to  domestic  efforts,  the  Chinese  government  also  seeks  to  obtain 
international  support  and  cooperation.    On  December  11,  2007,  the  SFDA  of  the 
People’s Republic of China and the Department of Health and Human Services of the 
United States of America signed the Agreement on the Safety of Drugs and Medical 
Devices (hereinafter referred as “the Agreement”).  The two parties understand the 
mutual benefits of protecting the public health through improved cooperation between 
the parties with regard to monitoring and regulating the safety of drugs and medical 
devices, and desire to work together to better ensure the safety and quality of drugs, 
excipients, and medical devices.
44   
 
The Agreement establishes a list of designated drugs and designated medical devices 
and requires registration and collaboration on them.  This mechanism is designed to 
help  protect  the  safety  of  imported/exported  drugs  and  medical  devices.    The 
requirements  for  SFDA  can  also  promote  the  systematic  development  of  drug 
regulation in China.  For example, according to the Agreement, “HHS/FDA shall 
consult  with  SFDA  to  assist  SFDA  in  understanding  HHS/FDA  Requirements  for 
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Designated Drugs and Designated Medical Devices.”
45  In this way, SFDA can get 
access to HHS/FDA’s relevant technological information and regulatory scheme, and 
improve its own regulatory arrangements.  HHS/FDA and SFDA will cooperate on 
identifying plausible and effective means to ensure the quality, safety, and authenticity 
of designated drugs.
46  The joint effort between the two agencies will consequently 
contribute to the reform of the Chinese drug regulation system.  In order to ensure the 
performance of responsibilities under the Agreement, documentation is required by 
the  Agreement.    “SFDA  shall  maintain  documents  on  file  related  to  reviews, 
inspections,  testing,  recalls,  compliance,  and  any  other  assessment  of  a  Firm  of 
Designated  Drugs  and  Designated  Medical  Devices.”
47   This  provision  puts  more 
burdens on SFDA to modernize and regularize its administrative actions. 
 
The Agreement is not only intended to promote understanding between the parties and 
recognize the differences between their systems, but also to address those differences 
and gaps.
48  Specifically, “SFDA shall actively create conditions to enable SFDA to 
certify that HHS/FDA Requirements are met for firms producing Designated Drugs 
and Designated Medical Devices intended for export to the United States.”
49   
 
Another  cooperative  aspect  in  the  Agreement  is  information  sharing  between  the 
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parties.  “The Parties shall exchange information related to Drugs, Excipients, and 
Medical  Devices  and  their  respective  regulatory  systems  concerning  Drugs, 
Excipients, and Medical Devices on a timeframe.”
50  Given access to the information 
about the regulatory systems by HHS/FDA, SFDA will be more active and creative in 
the reform and implementation of China’s new drug regulation system. 
 
Besides  all  the  cooperative  schemes  mentioned  above,  the  concrete  regulatory 
cooperative activities proposed in the Agreement will also have a profound impact on 
Chinese  drug  regulation  system  in  the  long  term.    The  regulatory  cooperative 
activities  include  “training  programs  and  scientific  discussions  or  cooperation, 
intended to support the long term stability and effectiveness of the registration and 
certification programs.”
51  Some of the appropriate regulatory cooperative activities 
are listed in the Agreement, such as:  
 
development  and  coordination  of  the  training  programs  for  Chinese 
inspectors; technical exchanges and training relating to the use of Good 
Clinical Practice (GCP) to ensure the safety of human subjects and the 
collection  of  valid  clinical  data;  and  training  and  exchange  on  the 
development  of evaluation  review  methods,  inspection  techniques, 
establishment of computer databases, evaluation report standard formats, 
and  the  development  of  technical  guidance  documents,  and  laws  and 
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regulations.
52   
 
Cooperation is also reflected in the promulgation process for relevant regulations.  
Before a regulation related to a designated drug is issued, the Agreement requires an 
open comment period.  “Except in extraordinary circumstances . . . each Party shall 
publish  on  its  website(s)  all  proposed  regulations  and  other  measures  related  to 
Designated Drugs and Designated Medical Devices and allow a reasonable period of 
time  for  all  interested  parties  to  submit  comments.”
53   This  provision  provides  a 
participation opportunity for all the interested parties.  In addition, “each Party shall 
consider such comments and, at the time final regulations are adopted, address in 
writing significant, substantive comments received from interested persons during the 
comment  period  and  explain  any  substantive  revision  made  to  the  proposed 
regulations.”
54   After  this  comment  and  review  process,  “both  Parties  shall  also 
publish on its website all final regulations and measures related to Designated Drugs 
and  Designated  Medical  Devices  and  allow  a  reasonable  amount  of  time  before 
implementation  and  enforcement. ”
55   What  is  provided  in  the  Agreement  is  quite 
similar to the rulemaking process in the U.S., which will increase public participation 
and transparency in rulemaking.   
 
The Agreement will assist and supervise SFDA on performing its responsibilities for 
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drug  regulation,  but  it  has  some  disadvantages  at  the  same  time.    Most  of  its 
requirements  are  limited  to  the  designated  drugs,  which  significantly  narrows  its 
effect on Chinese drug safety issues.  A large number of drugs will not be covered by 
the Agreement.  In addition, it mainly focuses on drugs for export to the US, which 
neglects the drugs sold within China.  In the end, it is not specifically tailored to the 
new drug regulation process, which is the subject of this paper.  Nevertheless, I would 
still consider the Agreement as a big success for public safety and health.  It is great to 
see the SFDA and HHS/FDA recognize the differences in each country and keep an 
open mind to technological and regulatory cooperation between them.  In the future, 
SFDA still faces more challenges and will need to maintain domestic and international 
access to better systems in the long term. 
 
Conclusion 
 
In response to the corruptions cases, the recent reform of the new drug regulation 
system of PRC has mainly focused on the supervision of government authority by 
supervisory  agencies  and  the  public.    The  tendency  of  stricter  supervision  of 
government power is obviously beneficial for the drug safety.   However, the effective 
implementation of legal schemes is still a big issue in China.  Because the supervisory 
agencies lack independent status, their supervision is seriously limited by the impact 
of  administrative  agencies.    On  the  side  of  the  public,  access  to  sufficient  and   31 
authentic government information has not been fully guaranteed under the current 
system.    The  capacity  of  public  participation  is  still  under  construction.  
Non-government organizations in China are facing many difficulties with regard to 
human  and  financial  resources.    Judicial  reform  is  still  underway  to  ensure  the 
independence of judicial agencies.  Therefore, the issue of drug safety is by all means 
a very complicated issue which involves both legal and social reform.  It will take a 
long time to realize a substantial transformation.  